Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M.
Kubesova B, et al. Among authors: kabathova j.
Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.
Leukemia. 2018.
PMID: 28744014
Free PMC article.